Special Issue "Molecular Mechanisms and Biomarkers in Drug-Induced Organ Injury"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 22010
Interests: biomarker; pharmacology; toxicology; autophagy; apoptosis; endoplasmic reticulum stress; exosome; miRNA; pharmacogenomics; toxicogenomics; reactive oxygen; anticancer drugs; immunosuppressive drugs; tyrosine kinase inhibitors
Special Issues, Collections and Topics in MDPI journals
Biomarkers reflecting, predicting, and associating pharmacological effects and/or toxicological disorders have been widely examined. Candidate molecules that act as potential biomarkers for drug-induced organ toxicity have been discovered. Endogenous compounds are well-applied in the clinical setting, such as creatinine, Na+, blood urea nitrogen, aminotransferase, bilirubin, and so on. Despite these classical markers, some peptides and miRNAs have been examined as new types of biomarkers.
In the field of nephrotoxicity, serum creatinine is usually examined for use as a conventional marker for renal damage in clinical treatment. However, this biochemical parameter is acknowledged to be non-specific to cover drug-induced kidney injury. Similar to kidney injury, drug-induced liver, lung, and bone marrow injury are often observed in pharmacotherapy and chemotherapy. Therefore, some organ-specific and/or drug-specific biological markers including functional proteins, peptides, nucleic acids, fatty acids, miRNAs, and so on are required to make accurate diagnosis.
Recently, the research area of biomarkers in pharmacology and toxicology has been expanded to find the physiological and pathophysiological significance in molecular-biological processes. With these exciting findings, this Special issue focuses on “Molecular Mechanisms and Biomarkers in Drug-Induced Organ Injury”.
Prof. Dr. Satohiro Masuda
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- molecular mechanisms and biomarkers in drug-induced kidney injury
- molecular mechanisms and biomarkers in drug-induced liver injury
- molecular mechanisms and biomarkers in drug-induced lung injury
- molecular mechanisms and biomarkers in drug-induced neuropathy
- molecular mechanisms and biomarkers in drug-induced bone marrow injury
- cancer chemotherapy
- anti-infectious treatment
- immunosuppressive drugs
- anti-diabetic drugs
- cardiovascular treatment
- anti-inflammatory bowel disease
- treatment against autoimmune disease